Identification of a rare EGFR exon 18 mutation in lung adenocarcinoma using targeted next-generation sequencing as a tool for precision medicine-Reference-Cited by-同舟云学术

Identification of a rare EGFR exon 18 mutation in lung adenocarcinoma using targeted next-generation sequencing as a tool for precision medicine

Published:2023 Issue:4 Volume:6 Page:589-592
ISSN:2590-3233
Container-title:Cancer Research, Statistics, and Treatment
language:en
Short-container-title:

Author:

Jha Prerana¹,Trivedi Vaishakhi¹,Biswal Ranendra¹,Chandrani Pratik²³⁴,Ramachandran Venkataramanan¹,Shah Minit⁵³,Choughule Anuradha²³,Noronha Vanita⁵³,Prabhash Kumar⁵³,Kumar Prashant¹

Affiliation:

1. Karkinos Healthcare Pvt Ltd, Navi Mumbai, Maharashtra, India

2. Medical Oncology – Molecular Laboratory, Tata Memorial Hospital, Mumbai, Maharashtra, India

3. Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, Maharashtra, India

4. Center for Computational Biology, Bioinformatics and Crosstalk Lab, Advanced Center for Treatment, Research, and Education in Cancer, Kharghar, Navi Mumbai, Maharashtra, India

5. Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India

Publisher

Medknow

Subject

Cancer Research,Oncology (nursing),Drug Guides,Oncology

Reference18 articles.

1. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer;Noronha;J Clin Oncol,2020

2. EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance;Uribe;Cancers (Basel),2021

3. Pathogenesis of lung cancer signalling pathways: Roadmap for therapies;Brambilla;Eur Respir J,2009

4. Emerging functions of the EGFR in cancer;Sigismund;Mol Oncol,2018

5. Tenen EGFR signaling pathway as therapeutic target in human cancers;Elena Levantini;Semin Cancer Biol,2022

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rare compound mutation of EGFR L858R and E709A identified in both solid tumor and liquid biopsy of a lung adenocarcinoma patient;Medical Reports;2024-08

2. Authors’ reply to Pai and Varghese, and Kenkre et al.;Cancer Research, Statistics, and Treatment;2024-01

3. NUT-midline carcinoma of the lung with rare BRD3-NUTM1 fusion;Cancer Research, Statistics, and Treatment;2024-01

4. A personalized approach to the management of rare genetic aberrations in oncology: A letter citing the EGFR exon 18 mutation molecular tumor board report;Cancer Research, Statistics, and Treatment;2024-01

5. Real but rare: Lessons from a case of lung adenocarcinoma with an uncommon EGFR exon 18 alteration;Cancer Research, Statistics, and Treatment;2024-01